# Response Summary

## Task
Reviewed the draft Pre-Submission (Q-Sub) package for the VascuClear 3000 catheter-based thrombectomy device and prepared a prioritized issue memorandum.

## Deliverable
`output/presub-issue-memorandum.docx` — a privileged attorney-work-product memorandum from Daniel J. Yoo (Senior Associate, Hargrove, Templeton & Bliss LLP) to Kate Pressman, reviewing all six enclosures plus the internal strategy email chain.

## Documents reviewed
1. Cover Letter (presub-cover-letter.docx)
2. Device Description and Predicate Comparison (Enclosure 1)
3. Proposed Testing Plan (Enclosure 2)
4. Clinical Study Synopsis (Enclosure 3)
5. Draft Instructions for Use (Enclosure 4)
6. ThrombEx 200 (K192847) 510(k) Summary (Enclosure 5 — the proposed predicate)
7. Internal email chain on regulatory/clinical strategy

## Approach
Read every document fully, then cross-referenced each document against every other relevant document to surface issues that exist only in the gaps between documents (e.g., the IFU's 72-hour indwell vs. the testing plan's <24-hour biocompatibility classification; the predicate's actual aspiration pressure vs. the comparison table's "not specified"; the "post-clearance" study characterization vs. the stated intent to support the 510(k)).

## Issues identified — 27 total, prioritized into four tiers
- **Tier 1 (Critical, 4 issues):** combination-product classification unresolved and not posed to FDA; clinical study mischaracterized as "post-clearance"/no IDE; substantial-equivalence rests on a predicate lacking the Device's two defining features (rotating impeller, drug-delivery lumen); cover letter omits the combination-product and IDE questions Kate Pressman recommended.
- **Tier 2 (High, 6 issues):** biocompatibility contact-duration misclassification; impeller fatigue test equating to ~2.5 seconds; software "Minor" level of concern lower than the predicate's "Moderate"; EMC testing omitted; indication drug-delivery claim; infeasible Dec 31, 2025 clearance milestone.
- **Tier 3 (Medium, 10 issues):** MRI testing absent with IFU "[TBD]" placeholders; clinical design (performance goal, endpoint mismatch, no PTS follow-up); flawed statistical power claim; saline-only drug testing; embolization/dynamic-hemolysis testing gaps; shelf-life and reprocessing validation; cross-document inconsistencies (console dimensions, impeller material, predicate population, predicate aspiration pressure, contacts); 72-hour indwell infection risk.
- **Tier 4 (Lower, 7 issues):** outdated guidance references; human factors; cybersecurity; coating integrity; materials-listing inconsistencies; budget figures in FDA-facing document; consent/GCP framing.

Each issue includes a precise citation to the source record, why it matters, and a concrete recommendation. A consolidated pre-filing action list and strategic/corporate considerations (Braddock Ventures milestone, financial runway, Kendrick & Hale involvement) are included.

## Validation
Generated via Pandoc (docx skill `generate_from_md.py`) and validated with `validate.py` — ECMA-376 schema-valid, ZIP integrity and relationship consistency confirmed (exit code 0).